Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Short-term Investments (2022 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Short-term Investments for 4 consecutive years, with $108.1 million as the latest value for Q4 2025.

  • Quarterly Short-term Investments rose 482.37% to $108.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $108.1 million through Dec 2025, up 482.37% year-over-year, with the annual reading at $108.1 million for FY2025, 482.37% up from the prior year.
  • Short-term Investments for Q4 2025 was $108.1 million at Whitehawk Therapeutics, down from $124.7 million in the prior quarter.
  • The five-year high for Short-term Investments was $133.5 million in Q4 2022, with the low at $3.5 million in Q1 2025.
  • Average Short-term Investments over 4 years is $60.9 million, with a median of $47.1 million recorded in 2022.
  • Peak annual rise in Short-term Investments hit 482.37% in 2025, while the deepest fall reached 89.87% in 2025.
  • Over 4 years, Short-term Investments stood at $133.5 million in 2022, then plummeted by 65.59% to $46.0 million in 2023, then crashed by 59.6% to $18.6 million in 2024, then surged by 482.37% to $108.1 million in 2025.
  • According to Business Quant data, Short-term Investments over the past three periods came in at $108.1 million, $124.7 million, and $32.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.